IntReALL 2020 International Study for Treatment of Childhood Relapsed ALL 2020
- Coordinator
- Charite - Universitaetsmedizin Berlin, Germany
- Runs
- 1 May 2023 to 30 April 2028
- Status
- Running
- EU funding
- €6.1m
- Total cost
- €6.1m
- Partners
- 26 organisations in 20 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101104582
What the project is doing
In the project's own words, from its summary on CORDIS.
Relapse of acute lymphoblastic leukemia (ALL) remains a leading cause of mortality in childhood cancer. IntReALL 2020 will conduct randomized and historically controlled trials in children with relapsed B-cell precursor (BCP) ALL with the aim to replace toxic chemotherapy with better tolerated and more efficacious immunotherapeutic drugs. In standard risk (SR) patients, the CD22 directed antibody-drug conjugate inotuzumab ozogamicin (InO) will be randomly compared with standard of care (SOC) ALL-R3 induction.
All patients will receive one SOC consolidation- and one Blina course, compared to historical controls. SR patients with MRD good response will receive 2 additional Blina courses replacing chemotherapy randomly compared with SOC. Patients with high-risk relapse will receive induction investigating InO versus ALL-R3 in an industry-sponsored trial, followed by IntReALL consolidation and allogeneic HSCT. Patients with isolated extramedullary (IEM) relapse are treated based on ALL-REZ BFM 2002 backbone.
IntReALL 2020 will establish a federated relapsed/refractory leukaemia board generating personalized recommendations based on clinical, molecular-genetic and drug response profiling data. Patients with very-high risk disease will receive experimental/personalized therapies, including a trial investigating CD19-directed chimeric receptor antigen (CAR) T-cells produced in academic institutions. Other CAR T-cells trials as well as an induction trial for T-ALL relapse will be developed.
Documentation and monitoring of the trials and the individualized treatment will be realized using the MARVIN database. Comprehensive statistical and data management activities will warrant the accuracy and interpretability of the data. IntReALL 2020 involves representatives from participating pharmaceutical companies and EMA as well as patient/parent advocates to discuss strategies for developing new drugs within academic trials warranting a benefit for all patients on the results.“This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment’.”
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Charite - Universitaetsmedizin Berlin | Berlin | Germany | Coordinator |
| St. Anna Kinderkrebsforschung GmbH | Wien | Austria | Participant |
| Universiteit Gent | Gent | Belgium | Participant |
| Universitat Zurich | Zurich | Switzerland | Associatedpartner |
| Fakultni Nemocnice Motol a Homolka | Praha 5 | Czechia | Participant |
| Gpoh Zdm Ggmbh | Hannover | Germany | Participant |
| Medizinische Hochschule Hannover | Hannover | Germany | Participant |
| Tp21 GmbH | Berlin | Germany | Participant |
| Region Hovedstaden | Hillerod | Denmark | Participant |
| Geniko Nosokomeio Paidon Athinon I Agia Sofia | Athina | Greece | Participant |
| Fundacion Para La Formacion E Investigacion Sanitarias De La Region De Murcia | Murcia | Spain | Participant |
| Servicio Murciano De Salud | Murcia | Spain | Third party |
| Hus-Yhtyma | Helsinki | Finland | Participant |
| Assistance Publique Hopitaux De Paris | Paris | France | Participant |
| Centre Hospitalier Universitaire De Nice | Nice | France | Participant |
| Imagine for Margo Children Without Cancer | Saint-Germain-En-Laye | France | Participant |
| Magyar Gyermekonkologiai Halozat -Magyar Gyermekonkologusok Es Gyermekhematologusok Tarsasaga | Budapest | Hungary | Participant |
| The Foundation for Medical Research Infrastructural Development and Health Services Next to the Medical Center Tel Aviv | Tel Aviv | Israel | Participant |
| Ospedale Pediatrico Bambino Gesu | Roma | Italy | Participant |
| Prinses Maxima Centrum Voor Kinderoncologie BV | Utrecht | Netherlands | Participant |
| Oslo Universitetssykehus Hf | Oslo | Norway | Participant |
| Uniwersytet Medyczny Im Piastow Slaskich We Wroclawiu | Wroclaw | Poland | Participant |
| Instituto Portugues De Oncologia De Lisboa Francisco Gentil Epe | Lisboa | Portugal | Participant |
| Institutul Clinic Fundeni | Bucuresti | Romania | Participant |
| Region Stockholm | Stockholm | Sweden | Participant |
| Univerzitetni Klinicni Center Ljubljana | Ljubljana | Slovenia | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI